The company manufactures fermentation-based biopharmaceutical active pharmaceutical ingredients (APIs) sold worldwide.

[3] It manufactures biopharmaceutical products across therapy segments such as immunosuppressant, oncology, antifungal, antibacterial and anthelmintic.

In 2005, Hyderabad-based Matrix Laboratories acquired 55% stake in the company, by buying partial shareholding of Vaid and Jhunjhunwala.

[8] After Matrix Laboratories was acquired by Mylan, the latter sold back its stake in Concord Biotech to Vaid and Jhunjhunwala in 2009.

[12][13] Quadria Capital sold its entire stake in Concord Biotech's 2023 initial public offering.